Ilya Pharma presents first in class wound healing treatment at US Defense Department’s MHSRS 2022 Conference in Florida
ILP100 accelerates wound healing in humans and suited for use in unconventional settings. The company is excited that the DoD have selected the project to participate at the annual medical partnering conference.
Uppsala, Sweden, September 12, 2022: Ilya Pharma (the Company), a clinical stage immunotherapy company presented results from a first in human trial using its novel ILP100-Topical drug candidate at the US Defense Department’s MHSRS Conference in Florida. In a major breakthrough, ILP100 uses transformed lactic acid bacteria to produce and release the human chemokine CXCL12 for